Immunogenic cell death (ICD)-inducers in non-small-cell lung carcinoma (NSCLC): current knowledge and future perspective

被引：0
作者：
Alireza Kashefizadeh
Hossein Kazemizadeh
机构：
[1] Shahid Beheshti University of Medical Sciences,Department of Pulmonology, Shahid Labbafinejad Hospital
[2] Tehran University of Medical Sciences,Advanced Thoracic Research Center
来源：
Clinical and Translational Oncology | 2023年 / 25卷
关键词：
Immunogenic cell death; Immunotherapy; Lung cancer; NSCLC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The prevalence of non-small-cell lung cancer (NSCLC) is rising every year all around the world. The interaction between cancer cells and the tumor microenvironment (TME) is a crucial factor in determining the development of human neoplasms. Organellar and cellular stress are induced during immunogenic cell death (ICD), a particularly functional response pattern. ICD is a separate but poorly characterized entity caused by various cancer treatments. The induction of ICD has the potential to change TME and the recruitment of tumor-infiltrating lymphocytes (TILs), and the coupling of ICD-inducers and other therapeutic approaches can have a synergistic role in boosting anticancer impacts. The purpose of this study is to review the studies in the field of NSCLC using ICD-inducers as a treatment strategy or as a combination therapy. This review provide for researches a better view of what has been done so far and the challenges they face in the future.
引用
收藏
页码：316 / 322
页数：6
相关论文
共 456 条
  • [41] Golab J(2012)Primary effusion lymphoma cell death induced by bortezomib and AG 490 activates dendritic cells through CD91 PLoS ONE 7 4954-73
  • [42] Vandenabeele P(2005)Select forms of tumor cell apoptosis induce dendritic cell maturation J Leukoc Biol 77 624-25
  • [43] Krysko DV(2011)Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor ApoptosisCTX and IFN-I synergism in DC-driven antitumor response Can Res 71 1062-1883
  • [44] Agostinis P(2010)Immunogenic death of colon cancer cells treated with oxaliplatin Oncogene 29 58-269
  • [45] Garg A(2008)Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone Can Res 68 15-318
  • [46] Martin S(2007)A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to Erlotinib Can Res 67 1869-1158
  • [47] Golab J(2011)Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody J Immunol 187 257-378
  • [48] Agostinis P(2016)The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death Nat Med 22 311-680
  • [49] Michaud M(2019)Priming anti-tumor immunity by radiotherapy: dying tumor cell-derived DAMPs trigger endothelial cell activation and recruitment of myeloid cells Oncoimmunology 8 1147-251
  • [50] Martins I(2012)A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death Embo J 31 361-1756
12345678910